SCHEMBL25899176

SCHEMBL25899176

CC(C)c1cc2c(O)nc(N)nc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.44
SLC2A1 P11166 1/20 0.44
EGFR P00533 3/20 0.34
KDR P35968 3/20 0.34
HRH4 Q9H3N8 2/20 0.33
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
AURKA O14965 1/20 0.31
PDPK1 O15530 1/20 0.31
TGFBR1 P36897 1/20 0.31
AURKB Q96GD4 1/20 0.31
HCAR3 P49019 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
TSHR P16473 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
HTR1B P28222 1/20 0.30
HTR2B P41595 1/20 0.30
GPR65 Q8IYL9 1/20 0.30
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24629148 0.77 HRH4 (0.53) DHFREGFRKDRHRH4
SCHEMBL30083300 0.77 HRH4 (0.53) DHFREGFRKDRHRH4
SCHEMBL16546228 0.69 HRH4 (0.60) DHFREGFRKDRHRH4AURKB
SCHEMBL22476345 0.68 HRH4 (0.58) DHFRHRH4TSHRHRH3
SCHEMBL14879331 0.65 ADORA1 (0.65) TSHR
SCHEMBL12938123 0.64 TSHR (0.37) DHFRSLC2A1IKBKBCHUKHCAR3
SCHEMBL14197880 0.63 CHUK (0.38) IKBKBCHUK
SCHEMBL13975888 0.63 NPC1 (0.45) DHFRSLC2A1
SCHEMBL13188053 0.63 TSHR (0.35) DHFRSLC2A1IKBKBCHUKHCAR3
SCHEMBL12495442 0.63 ADORA2A (0.35) DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A DHFR 2599/4885SLC2A1 2101/4885EGFR 60/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B DHFR 4085/4885SLC2A1 1778/4885EGFR 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.